NEW
Toujeo

Toujeo

insulin glargine

Manufacturer:

sanofi-aventis

Distributor:

DKSH
Concise Prescribing Info
Contents
Insulin glargine
Indications/Uses
DM in adults, adolescents & childn from 6 yr.
Dosage/Direction for Use
Individualized dosage. Type 1 DM Once daily w/ short-/rapid-acting insulin & requires individual dose adjustments. Type 2 DM Initially 0.2 u/kg followed by individual dose adjustments, may be given w/ other antihyperglycaemic products.
Contraindications
Special Precautions
Not to be administered IV, not to be used in insulin infusion pumps. Not for diabetic ketoacidosis. Patients w/ significant coronary arteries stenosis or blood vessels supplying the brain, proliferative retinopathy; patients in whom glycaemic control is markedly improved, hypoglycaemia develops gradually & autonomic neuropathy is present, after transfer from animal to human insulin, long history of diabetes, suffering from psychiatric illness, receiving concurrent treatment w/certain other medicinal products; change in the inj area, improved insulin sensitivity (eg, removal of stress factors), unaccustomed, increased or prolonged physical activity, intercurrent illness (eg, vomiting, diarrhoea), inadequate food intake, missed meals, alcohol consumption, certain uncompensated endocrine disorders (eg, hypothyroidism & anterior pituitary or adrenocortical insufficiency); switching between & from other insulins. Formation of insulin Ab. Combination w/ pioglitazone. May affect ability to drive & use machines. Lactation. Childn <6 yr. Elderly ≥65 yr.
Adverse Reactions
Hypoglycaemia. Lipohypertrophy; inj site reactions ie, redness, pain, itching, hives, swelling, inflammation.
Drug Interactions
Enhanced blood glucose-lowering effect w/ antihyperglycaemics, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, pentoxifylline, propoxyphene, salicylates, sulfonamides. Reduced blood glucose-lowering effect by corticosteroids, danazol, diazoxide, diuretics, glucagon, INH, oestrogens & progestogens, phenothiazine derivatives, somatropin, sympathomimetics [eg, epinephrine (adrenaline), salbutamol, terbutaline], thyroid hormones, atypical antipsychotics (eg, clozapine, olanzapine), PIs. Potentiated or weakened blood glucose-lowering effect w/ β-blockers, clonidine, lithium salts or alcohol. Hypoglycemia sometimes followed by hyperglycemia w/ pentamidine. Reduced or absent signs of adrenergic counterregulation w/ sympatholytics eg, guanethidine, reserpine.
ATC Classification
A10AE04 - insulin glargine ; Belongs to the class of long-acting insulins and analogues for injection. Used in the treatment of diabetes.
Presentation/Packing
Form
Toujeo soln for inj 300 units/mL
Packing/Price
1.5 mL x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in